TY - JOUR
T1 - No SARS-CoV-2 detection in the German CAPNETZ cohort of community acquired pneumonia before COVID-19 peak in March 2020
AU - Members of the CAPNETZ study group
AU - Panning, Marcus
AU - Wiener, Julius
AU - Rothe, Kathrin
AU - Schneider, Jochen
AU - Pletz, Mathias W.
AU - Rohde, Gernot
AU - Rupp, J.
AU - Witzenrath, M.
AU - Spinner, Christoph D.
AU - Dreher, M.
AU - Cornelissen, C.
AU - Knüppel, W.
AU - Stolz, D.
AU - Suttorp, N.
AU - Bauer, W.
AU - Mikolajewska, A.
AU - Witzenrath, M.
AU - Pankow, W.
AU - Gläser, S.
AU - Thiemig, D.
AU - Prediger, M.
AU - Schmager, S.
AU - Kolditz, M.
AU - Schulte-Hubbert, B.
AU - Langner, S.
AU - Rohde, G.
AU - Bellinghausen, C.
AU - Panning, M.
AU - Hoffmann, C.
AU - Welte, T.
AU - Freise, J.
AU - Barten, G.
AU - Kröner, W.
AU - Nawrocki, M.
AU - Naim, J.
AU - Illig, T.
AU - Klopp, N.
AU - Pletz, M.
AU - Kroegel, C.
AU - Schleenvoigt, B.
AU - Forstner, C.
AU - Moeser, A.
AU - Drömann, D.
AU - Parschke, P.
AU - Franzen, K.
AU - Käding, N.
AU - Wouters, M.
AU - Walraven, K.
AU - Braeken, D.
N1 - Funding Information:
Open Access funding provided by Projekt DEAL. CAPNETZ is a multidisciplinary approach to better understand and treat patients with community-acquired pneumonia. The network has only been made possible by the contribution of many investigators. We are especially indebted to the work of the investigators in the local clinical centres (LCC) who established and kept contact to all practitioners, physicians, and respiratory specialists cooperating within the network. Members of the CAPNETZ study group except the authors: M. Dreher, C. Cornelissen (Aachen); W. Kn?ppel (Bad Arolsen); D. Stolz (Basel, Switzerland); N. Suttorp, W. Bauer, A. Mikolajewska, M. Witzenrath, W. Pankow, S. Gl?ser, D. Thiemig (Berlin); M. Prediger, S. Schmager (Cottbus); M. Kolditz, B. Schulte-Hubbert, S. Langner (Dresden); G. Rohde, C. Bellinghausen (Frankfurt); M. Panning (Freiburg); C. Hoffmann (Hamburg); T. Welte, J. Freise, G. Barten, W. Kr?ner, M. Nawrocki, J. Naim, T. Illig, N. Klopp (Hannover); M. Pletz, C. Kroegel, B. Schleenvoigt, C. Forstner, A. Moeser (Jena); D. Dr?mann, P. Parschke, K. Franzen, J. Rupp, N. K?ding (L?beck); M. Wouters, K. Walraven, D. Braeken (Maastricht, The Netherlands); C. Spinner (Munich); A. Zaruchas (Paderborn); Schaberg, D. Heigener, I. Hering (Rotenburg/W?mme); W. Albrich, F. Waldeck, F. Rassouli, S. Baldesberger (St. Gallen, Switzerland); S. Stenger, M. Wallner (Ulm); H. Burgmann, L. Traby (Vienna); and all study nurses.
Publisher Copyright:
© 2020, The Author(s).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Purpose: The first SARS-CoV-2 cases in Europe were reported in January 2020. Recently, concern arose on unrecognized infections before this date. For a better understanding of the pandemic, we retrospectively analyzed patient samples for SARS-CoV-2 from the prospective CAPNETZ study cohort. Methods: We used nasopharyngeal swab samples from a cohort of well characterized patients with community acquired pneumonia of the CAPNETZ study group, recruited from different geographic regions across Germany, Austria, the Netherlands, and Switzerland between 02nd December 2019 and 28th April 2020. Multiplex real-time RT-PCR for a broad range of respiratory pathogens and SARS-CoV-2 real-time RT-PCR were performed on all samples. Results: In our cohort, respiratory pathogens other than SARS-CoV-2 were detected in 21.5% (42/195) of patients with rhinovirus as the most frequently detected pathogen. The detection rate increased to 29.7% (58/195) when SARS-CoV-2 was included. No SARS-CoV-2 positive sample was detected before end of March 2020. Conclusions: Respiratory viral pathogens accounted for a considerable number of positive results but no SARS-CoV-2 case was identified before the end of March 2020.
AB - Purpose: The first SARS-CoV-2 cases in Europe were reported in January 2020. Recently, concern arose on unrecognized infections before this date. For a better understanding of the pandemic, we retrospectively analyzed patient samples for SARS-CoV-2 from the prospective CAPNETZ study cohort. Methods: We used nasopharyngeal swab samples from a cohort of well characterized patients with community acquired pneumonia of the CAPNETZ study group, recruited from different geographic regions across Germany, Austria, the Netherlands, and Switzerland between 02nd December 2019 and 28th April 2020. Multiplex real-time RT-PCR for a broad range of respiratory pathogens and SARS-CoV-2 real-time RT-PCR were performed on all samples. Results: In our cohort, respiratory pathogens other than SARS-CoV-2 were detected in 21.5% (42/195) of patients with rhinovirus as the most frequently detected pathogen. The detection rate increased to 29.7% (58/195) when SARS-CoV-2 was included. No SARS-CoV-2 positive sample was detected before end of March 2020. Conclusions: Respiratory viral pathogens accounted for a considerable number of positive results but no SARS-CoV-2 case was identified before the end of March 2020.
UR - http://www.scopus.com/inward/record.url?scp=85087463560&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/0288db88-fdab-3c2e-8cdb-9ede45f84343/
U2 - 10.1007/s15010-020-01471-y
DO - 10.1007/s15010-020-01471-y
M3 - Letters
C2 - 32621281
AN - SCOPUS:85087463560
SN - 0300-8126
VL - 48
SP - 971
EP - 974
JO - Infection
JF - Infection
IS - 6
ER -
